CD38 reduces mitochondrial fitness and cytotoxic T cell response against viral infection in lupus patients by suppressing mitophagy

被引:50
作者
Chen, Ping-Min [1 ]
Katsuyama, Eri [1 ]
Satyam, Abhigyan [1 ]
Li, Hao [1 ]
Rubio, Jose [1 ]
Jung, Sungwook [2 ]
Andrzejewski, Sylvia [3 ]
Becherer, J. David [3 ,4 ]
Tsokos, Maria G. [1 ]
Abdi, Reza [2 ]
Tsokos, George C. [1 ]
机构
[1] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA
[2] Harvard Med Sch, Transplantat Res Ctr, Brigham & Womens Hosp, Renal Div, Boston, MA USA
[3] Mitobridge Inc, Cambridge, MA USA
[4] Evotec Inc, 303B Coll Rd East, Princeton, NJ USA
关键词
N-ACETYLCYSTEINE; DISEASE-ACTIVITY; ERYTHEMATOSUS; DYSFUNCTION; ACTIVATION; COMPLEX; PRONE; AUTOIMMUNITY; LYMPHOCYTES; RAPAMYCIN;
D O I
10.1126/sciadv.abo4271
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Infection is one of the major causes of mortality in patients with systemic lupus erythematosus (SLE). We previously found that CD38, an ectoenzyme that regulates the production of NAD(+), is up-regulated in CD8(+) T cells of SLE patients and correlates with the risk of infection. Here, we report that CD38 reduces CD8(+) T cell function by negatively affecting mitochondrial fitness through the inhibition of multiple steps of mitophagy, a process that is critical for mitochondria quality control. Using a murine lupus model, we found that administration of a CD38 inhibitor in a CD8(+) T cell-targeted manner reinvigorated their effector function, reversed the defects in autophagy and mitochondria, and improved viral clearance. We conclude that CD38 represents a target to mitigate infection rates in people with SLE.
引用
收藏
页数:13
相关论文
共 53 条
  • [21] Innate immunity to influenza virus infection
    Iwasaki, Akiko
    Pillai, Padmini S.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2014, 14 (05) : 315 - 328
  • [22] Nicotinamide-induced Mitophagy EVENT MEDIATED BY HIGH NAD+/NADH RATIO AND SIRT1 PROTEIN ACTIVATION
    Jang, So-young
    Kang, Hyun Tae
    Hwang, Eun Seong
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (23) : 19304 - 19314
  • [23] Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus
    Kang, I
    Quan, T
    Nolasco, H
    Park, SH
    Hong, MS
    Crouch, J
    Pamer, EG
    Howe, JG
    Craft, J
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 172 (02) : 1287 - 1294
  • [24] The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to Infections
    Katsuyama, Eri
    Suarez-Fueyo, Abel
    Bradley, Sean J.
    Mizui, Masayuki
    Marin, Ana V.
    Mulki, Lama
    Krishfield, Suzanne
    Malavasi, Fabio
    Yoon, Joon
    Sui, Shannan J. Ho
    Kyttaris, Vasileios C.
    Tsokos, George C.
    [J]. CELL REPORTS, 2020, 30 (01): : 112 - +
  • [25] Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
    Khamashta, Munther
    Merrill, Joan T.
    Werth, Victoria P.
    Furie, Richard
    Kalunian, Kenneth
    Illei, Gabor G.
    Drappa, Jorn
    Wang, Liangwei
    Greth, Warren
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (11) : 1909 - 1916
  • [26] Ubiquitin is phosphorylated by PINK1 to activate parkin
    Koyano, Fumika
    Okatsu, Kei
    Kosako, Hidetaka
    Tamura, Yasushi
    Go, Etsu
    Kimura, Mayumi
    Kimura, Yoko
    Tsuchiya, Hikaru
    Yoshihara, Hidehito
    Hirokawa, Takatsugu
    Endo, Toshiya
    Fon, Edward A.
    Trempe, Jean-Francois
    Saeki, Yasushi
    Tanaka, Keiji
    Matsuda, Noriyuki
    [J]. NATURE, 2014, 510 (7503) : 162 - +
  • [27] Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial
    Lai, Zhi-Wei
    Kelly, Ryan
    Winans, Thomas
    Marchena, Ivan
    Shadakshari, Ashwini
    Yu, Julie
    Dawood, Maha
    Garcia, Ricardo
    Tily, Hajra
    Francis, Lisa
    Faraone, Stephen V.
    Phillips, Paul E.
    Perl, Andras
    [J]. LANCET, 2018, 391 (10126) : 1186 - 1196
  • [28] N-Acetylcysteine Reduces Disease Activity by Blocking Mammalian Target of Rapamycin in T Cells From Systemic Lupus Erythematosus Patients A Randomized, Double-Blind, Placebo-Controlled Trial
    Lai, Zhi-Wei
    Hanczko, Robert
    Bonilla, Eduardo
    Caza, Tiffany N.
    Clair, Brandon
    Bartos, Adam
    Miklossy, Gabriella
    Jimah, John
    Doherty, Edward
    Tily, Hajra
    Francis, Lisa
    Garcia, Ricardo
    Dawood, Maha
    Yu, Jianghong
    Ramos, Irene
    Coman, Ioana
    Faraone, Stephen V.
    Phillips, Paul E.
    Perl, Andras
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (09): : 2937 - 2946
  • [29] Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
  • [30] Exhausted Cytotoxic Control of Epstein-Barr Virus in Human Lupus
    Larsen, Martin
    Sauce, Delphine
    Deback, Claire
    Arnaud, Laurent
    Mathian, Alexis
    Miyara, Makoto
    Boutolleau, David
    Parizot, Christophe
    Dorgham, Karim
    Papagno, Laura
    Appay, Victor
    Amoura, Zahir
    Gorochov, Guy
    [J]. PLOS PATHOGENS, 2011, 7 (10):